Table 3.
Immunological Characteristics of HIV-Infected Women in Three Screening Centers, Southwest Ethiopia, 2018 (N=444)
| Variables | Frequency | Percentage | |
|---|---|---|---|
| Current use of HAART | Yes | 280 | 63 |
| No | 164 | 37 | |
| Current HAART use duration (N=280) | < 12 months | 58 | 20.7 |
| 12–36 months | 99 | 35.3 | |
| >36 months | 123 | 44 | |
| Base line CD4 count before HAART (N=280) | <200 | 245 | 87.5 |
| >200 | 35 | 12.5 | |
| Mean (±Std. Deviation) | 130.9(SD±52.4) | ||
| Recent CD4 count after HAART (N=280) | <200 | 72 | 25.7 |
| >200 | 208 | 74.3 | |
| Mean (±Std. Deviation) | 312.93(SD±219.38) | ||
| Ever history of smoking | Yes | 32 | 7.2 |
| No | 412 | 92.8 | |
| Who clinical stage | Stage one | 335 | 75.5 |
| Stage two | 64 | 14.4 | |
| Stage three | 45 | 10.1 | |